Oncotelic Therapeutics Expands into AI-Enhanced Robotics Through Strategic Partnership with TechForce Robotics

Oncotelic Therapeutics (OTCQB: OTLC) is moving beyond its roots as a clinical-stage biotechnology company into the quickly expanding intersection of artificial intelligence and industrial automation. Through two closely aligned announcements, the firm has unveiled a strategic partnership with TechForce Robotics, which positions it to commercialize a next-generation, AI-enhanced platform created for regulated pharmaceutical environments.

At the core of this pivot is Oncotelic’s proprietary PDAOAI platform, an AI-driven system designed to improve compliance, monitoring, and operational intelligence. By integrating this innovation with TechForce Robotics’ hardware and manufacturing expertise, the companies aim to deliver a GMP-compliant robotics solution capable of automating critical workflows in pharmaceutical production and laboratory settings. The partnership leverages TechForce's experience in building precision robotic systems for cleanroom environments, while Oncotelic contributes its deep understanding of regulatory requirements and quality control in drug manufacturing.

This strategic move signals a broader trend where biotech firms are diversifying into adjacent technology sectors to capitalize on their data and compliance expertise. For Oncotelic, the partnership offers an opportunity to generate near-term revenue streams while continuing its core drug development programs. The company’s CEO, Dr. Vuong Trieu, holds over 150 patent applications and 39 issued U.S. patents, many of which cover AI and automation technologies that could be applied beyond oncology.

Oncotelic remains focused on its primary mission: developing therapies for high-unmet-need cancers and rare pediatric indications. However, the robotics initiative represents a pragmatic approach to monetizing its intellectual property and technical capabilities. The company currently owns 45% of GMP Bio, a joint venture that advances its own pipeline of drug candidates, further complementing Oncotelic’s strategic position in oncology and rare disease therapeutics. The partnership with TechForce Robotics is expected to accelerate the deployment of AI-driven automation in pharmaceutical settings, potentially reducing production errors and increasing efficiency in drug manufacturing.

For investors, this announcement underscores Oncotelic's ability to pivot and adapt in a dynamic market. The robotics market in healthcare and pharmaceuticals is projected to grow significantly, and Oncotelic’s early entry could provide a competitive edge. To view the full article, visit https://ibn.fm/FnE7R. The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC.